TTP founded a partnership with IDDD, formerly the John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC CG) which was formed in 2003. The Consortium for Innovative Drug Discovery and Development (GCC IDDD) is a research consortium focused on providing support for Houston/Galveston scientists in advancing their therapeutics discoveries through development to the clinic. IDDD support includes collaborative networking and joint funding opportunities, shared core resources, and educational programs. With the desire to maximize screening capabilities while minimizing duplication of effort and resources, the IDDD has supported Gulf Coast investigators with an integrated capability to perform high throughput screening projects. Currently IDDD comprised a shared core networks including 11 core facilities from institutions including UT-Austin, Baylor College of Medicine (BCM), Rice University (Rice), (University of Houston (UH), University of Texas Health Science Center at Houston (UTHSC-H), University of Texas Medical branch at Galveston (UTMB-G), and University of Texas at M.D. Anderson Cancer Center (UTMDACC). As a member of IDDD, the core users could have access to use of facilities located at IDDD member institutions at regular (or internal) rates. This partnership benefited UT-Austin scientists with facile access to more complicated screening such as cell-based image and siRNA in addition to vigorous collaborations across the State of Texas. Learn more…
Center for Innovative Drug Discovery, UTSA
Combinatorial Drug Discovery Program, IBT
GCC-Center for comprehensive PK/PD and Formulation, TSU
GCC Integrated Microscopy Core, BCM
Accelerator for Cancer Therapeutics, TMC Innovation
Antibody Engineering and Expression Service Center, UTHealth
GCC Flow Cytometry and Cell Sorting Facility, IBT
RNA Core, HMRI
Preclinical Development Core for Large Molecule Therapeutics, UTHealth
Therapeutic Antibody Core, UTHealth